Purpose: Activation of Toll-like receptors (TLR) 7 and 8 by engineered agonists has been shown to aid in combating viruses and tumors. Here, we wished to test the effect of TLR7/8 activation on monocyte Fcγ receptor (FcγR) function, as they are critical mediators of antibody therapy.
FcγR transcript and protein, upregulating the activating FcγR and downregulating the inhibitory FcγRIIb. Studies using bone marrow-derived macrophage (BMM) from wild-type (WT) and knockout mice showed that TLR7 and MyD88 are required for the changes in FcγR. Functional assays showed that R-848 treatment synergizes with FcγR function both in vitro and in a murine solid tumor model. Hence, TLR7/8 is a novel regulator of FcγR expression and function, suggesting that TLR7/8 agonists may be especially effective as adjuvants for antibody therapy.
Materials and Methods
Antibodies and reagents. R-848 (Resiquimod) was purchased from Alexis Biochemicals and dissolved to 10 mmol/L in DMSO then to 1 mmol/L in RPMI 1640 for working stock. Brefeldin A was purchased from BioLegend and used according to the manufacturer's instructions. PCR primer sets FcγRIa, QT00013475; FcγRIIa, QT01667099; FcγRIIb, QT00086842; γ-subunit, QT00055853; TRAF3, QT00080990; glyceraldehyde-3-phosphate dehydrogenase (GAPDH), QT01192646] were from Qiagen. Trizol was purchased from Invitrogen. Reverse transcriptase, random hexamers, and SYBR Green PCR mix were purchased from Applied Biosystems. F(ab') 2 of anti-FcγRI (32.2) and anti-FcγRIIa (IV.3) were obtained from Medarex. The anti-FcR-γ-subunit was from Upstate Cell Signaling. Rabbit polyclonal antibodies specific to hFcγRIIa and hFcγRIIb were generated as previously described (13) . Actin, GAPDH, and horseradish peroxidase-conjugated antibodies were from Santa Cruz Biotechnology.
Western blotting and ELISAs. Cells were lysed in TN1 buffer [50 mmol/L Tris (pH 8.0), 10 mmol/L EDTA, 10 mmol/L Na 4 P 2 O 7 , 10 mmol/L NaF, 1% Triton X-100, 125 mmol/L NaCl, 10 mmol/L Na 3 VO 4 , and 10 μg/mL each aprotinin and leupeptin]. Postnuclear proteinmatched lysates were boiled in Laemmli sample buffer and separated by SDS-PAGE, transferred to nitrocellulose membranes, probed with the antibody of interest then developed by enhanced chemiluminescence (GE Healthcare). Cell supernatants were collected, centrifuged at full speed to clear cellular debris then assayed for cytokine through sandwich ELISA (R & D Systems) according to manufacturer protocol.
Real-time reverse transcription-PCR. RNA was extracted from peripheral blood monocyte (PBM) using Trizol, reverse transcribed to cDNA then run in triplicate for each donor on an Applied Biosystems Step One Plus system, with automatically calculated thresholds. Relative expression was calculated as 2^− ΔCt , with ΔCt calculated by subtracting the average cycle threshold (Ct) of two housekeeping controls (TRAF3 and GAPDH) from the experimental sample Ct (14) . BMM isolation and culture. L929 cells, generously provided by Dr. Stéphanie Seveau (The Ohio State University, Columbus, OH), were used to generate conditioned media for culturing of murine BMMs (15) . L929 were incubated in minimum essential media (Invitrogen) containing 10% heat-inactivated fetal bovine serum (FBS; Hyclone), nonessential amino acids, sodium pyruvate, and penicillin/ streptomycin (Invitrogen). Conditioned media from the L929 cells was collected after 7 d, passed through a 0.22-μm filter, and added to the BMM media. BMM were cultured from femurs of WT, TLR7
−/− , MyD88 −/− , TRIF −/− , and Cryopyrin −/− C57/Bl6 mice (16) by flushing the marrow from femurs and plating cells on plastic dishes in DMEM (Invitrogen) containing 10% FBS, 0.1% β-mercaptoethanol (Bio-Rad), and 30% conditioned media from L929 cells. After 6 to 7 d, nonadherent cells were washed away using PBS then the remaining BMM was used for experiments. Peripheral blood monocyte isolation. PBMs were isolated from Red Cross leukopaks through Ficoll centrifugation (Mediatech) followed by CD14-positive selection using MACS (Miltenyi Biotec, Inc.) as previously described (14) . PBMs were resuspended in RPMI 1640 containing 10% heat-inactivated FBS (Hyclone), penicillin/ streptomycin, and L-glutamate (Invitrogen). The purity of monocytes obtained was >97%, as determined by flow cytometry with CD14 antibody.
Microarray analysis. RNA was extracted from PBM using Trizol (Invitrogen) then labeled and hybridized to Affymetrix hgu133plus2 chips at The Ohio State University Medical Center Microarray-Genetics core facility. Resulting data files were preprocessed and analyzed using R (17) and BioConductor (18), testing for differentially expressed genes using the "limma" package (19) .
ADCC assay. ADCC assays were done as previously described (20, 21) . Briefly, PBM were incubated overnight with or without 1 μmol/L R-848 or 10 ng/mL IFNγ and were used as the effector cells. MDA-MB-468 breast cancer cells were used as the targets. These cells were incubated at 37°C with 0.3 mCi
51
Cr for 30 to 60 min, then incubated with no antibody, 10 μg/mL of Rituximab (negative control antibody), or with cetuximab. Monocytes and MDA cells were then coincubated at a 50:1 ratio in V-bottomed 95-well plates for 18 h. Supernatants were harvested
Translational Relevance
Antibody therapy against tumors has proven to be a valuable tool in combating cancer but is only partially effective or ineffective for many patients. Because of this, there is a continued attempt to find means of enhancing the efficacy of antibody treatment. Here, we provide both functional and mechanistic evidence that activation of TLR7/8 enhances FcγR expression and activity. Treatment with the TLR7/8 agonist R-848 leads to enhanced destruction of antibody-coated tumor cells by monocytes in vitro and to attenuated growth of solid tumors in vivo. Hence, TLR7/8 agonists may be an effective adjuvant for antibody therapy.
and counted for radiolabeled Chromium using a γ counter. Percent cytotoxicity was calculated as [(sample − minimum control)/(maximum control − minimum control) * 100], in which minimum controls were target cells incubated alone and maximum controls were target cells incubated alone and lysed using 10% SDS. To derive values for antibody-dependent cytotoxicity, values from no-antibody controls were subtracted from values from cetuximab-treated targets.
Murine solid tumor model. CT26-HER2/neu colon carcinoma cells (22) were grown in RPMI 1640 supplemented with 10% FBS, penicillin/streptomycin, and L-glutamate; washed to remove nonadherent cells; then resuspended using enzyme-free cell dissociation buffer (Invitrogen). Cells were centrifuged and resuspended at 10 × 10 6 per milliliter in RPMI 1640. The murine tumor model was performed in accordance with Penichet et al. (22) 2 ], in which length was the longest diameter of the tumor. Treatments consisted of 4D5 anti-HER2 antibody at 1 mg/kg, R-848 at 100 μg/kg, 4D5 plus R-848, or DMSO vehicle control. All in vivo experiments were done in strict accordance to guidelines set by the Institutional Animal Care and Use Committee.
Statistical analyses. For all experiments done in vitro, Student's t tests were used to test for statistically significant differences. Statistics for the murine solid tumor model experiment were done by the Center for Biostatistics at The Ohio State University. Briefly, data were transformed by cube root, then a linear mixed model was applied, followed by an interaction contrast to test for synergy. The SAS (SAS Institute, Inc.) software was used to analyze the in vivo experiment.
Results
R-848 enhances FcγR function. The TLR7/8 agonist R-848 has been shown to increase cytokine production (23), so we asked whether it would lead to an additive or synergistic increase in FcγR-mediated cytokine production. To test this, we incubated PBM overnight with 1 μmol/L R-848 then plated them on immobilized IgG to cluster the FcγR. As shown in Fig. 1A , R-848 treatment alone caused PBM to secrete tumor necrosis factor α (TNFα). However, when R-848 treatment and FcγR activation were combined, there was a superadditive level of TNFα secretion. This suggests that the TLR7/8 pathways functionally synergize with FcγR.
Next, we examined the ability of R-848 to enhance the destruction of antibody-coated tumor cells in vitro. We treated human PBM overnight with or without 1 μmol/L R-848 then tested them in an ADCC assay (24, 25) using cetuximab-coated MDA-MB-468 cells. Because it has been shown that IFNγ can enhance ADCC in human monocytes (26) (27) (28) , we also used 10 ng/mL IFNγ as a positive control. Results showed that R-848 treatment significantly increased antibody-dependent cytotoxicity, even to levels approaching those seen after IFNγ treatment (Fig. 1B) . Hence, R-848 promotes the destruction of antibodycoated tumor target cells in vitro.
Microarray analysis of R-848. We next examined the genomewide transcriptional responses of monocytes to R-848 in an effort to gain insights on how it enhanced monocyte function. To do this, we incubated PBM with 1 μmol/L R-848 for 18 h, extracted RNA, and performed Affymetrix microarray analysis. We then searched for significantly different transcripts within the "immune response" or "inflammatory" ontologies that were upregulated 2-fold or more and with an average log 2 expression of 3 or higher. There were a total of 119 unique transcripts, shown in Table 1 . As expected based on previous literature, we found upregulation of cytokines such as interleukin (IL)-6, IL-12 p40, and TNFα. FcγRs are critical for antibody-mediated clearance of tumor cells, such as that seen in Fig. 1B (29) . It was possible that part of the R-848-mediated Research.
on October 15, 2017. © 2010 American Association for Cancer clincancerres.aacrjournals.org Downloaded from enhancement of this clearance was due to the upregulation of these receptors and this was found in the analysis results (Table 1 , gray highlights). Unlike this upregulation of activating FcγR, the array data showed a 6-fold downregulation of the inhibitory FcγRIIb (data not shown). These results suggest that R-848 regulates FcγR at the transcriptional level and that this may largely account for the increased FcγR-mediated cytokine production and ADCC.
R-848 alters FcγR protein expression. We next verified that the altered transcription of FcγR led to changes in protein expression and tested for the lowest required dosage. We treated PBM overnight with 0, 0.01, 0.1, or 1.0 μmol/L R-848, or with 0, 1, 10, or 100 μmol/L R-848. Western blots were done to measure expression of FcγRIIa, the common γ-subunit, and FcγRIIb. As shown in Fig. 2A and B, a dosage of 1 μmol/L was sufficient to alter FcγR expression and higher dosages did not lead to greater changes.
To confirm that changes in FcγR also occurred on the cell surface, we treated PBM overnight with 1 μmol/L R-848 and measured surface expression of FcγRIa and FcγRIIa using flow cytometry. Compared with nontreated PBM, there were significant increases after R-848 treatment (Fig. 2C) . Overnight treatments (14-18 hours) with R-848 elicited changes in FcγR, so we next tested whether short (1-3 hours) treatment times would be sufficient. Hence, we treated PBM for 1, 3, or 14 hours then measured FcγR by Western blotting. Results showed that increases in FcγRIIa occurred at the late stage (Fig. 2D, top) , whereas small increases in the γ-chain appeared at 3 hours but were higher at 14 hours (Fig. 2D, middle) . However, decreases in FcγRIIb protein were seen within 1 hour (Fig. 2D, bottom) , whereas the transcript for FcγRIIb remained to 4 hours (data not shown). This suggests that R-848 triggered an immediate degradation of the FcγRIIb protein, followed by a later reduction in FcγRIIb transcript.
Secreted factors mediate increases in activating FcγR. Results from the microarray analysis showed that numerous cytokines were upregulated, many of which were known to influence FcγR expression. To test whether secretion of these cytokines may have been responsible for the R-848-mediated changes in FcγR, we pretreated PBM for 30 minutes with Brefeldin A, an inhibitor of secretion. Following this, PBM were treated for 12 hours with R-848 and FcγR expression was measured by both real-time reverse transcription-PCR and Western blotting. Results showed that pretreatment with Brefeldin A prevented the R-848-mediated increases in FcγRI, FcγRIIa, and γ-subunit transcripts, whereas the decrease in FcγRIIb was not affected (Fig. 3A) . Similarly, Western blotting showed that Brefeldin A pretreatment inhibited the R-848-mediated increases in FcγRIIa and the γ-subunit but did not prevent the reduction in FcγRIIb (Fig. 3B) . These results suggest that R-848 drives production of secreted factors that act in an autocrine/paracrine fashion to increase expression of the activating FcγR, but that the effect of R-848 on FcγRIIb is mediated through a different mechanism.
Mechanisms of R-848-mediated regulation of FcγR. We next wished to test whether a similar effect of R-848 on FcγR expression would occur in mice and to determine the mechanism by which R-848 mediates its effects. R-848 signals through the MyD88 adapter protein (30) and the Nalp3/Cryopyrin cytosolic sensor (31). To determine which were required for regulation of FcγR and to rule out a role for the MyD88-independent TRIF, we isolated BMMs from WT, TLR7 −/− , MyD88 −/− , TRIF −/− , and Cryopyrin −/− mice. BMMs were treated overnight with (32) . As shown in Fig. 4A (top and middle, respectively), neither TLR7 −/− nor MyD88 −/− cells showed R-848-mediated increases in the γ-subunit. However, R-848 did increase γ-subunit expression in Cyropyrin and TRIF knockout BMM (Fig. 4A, top and  bottom, respectively) . These results indicate that R-848-mediated effects on FcγR require TLR7 and MyD88. As a functional control, TNFα production was also examined in supernatants from BMM treated with or without R-848. Results were in accordance with those previously reported by Hemmi et al. (30) , showing that TLR7 −/− and MyD88
−/− cells did not produce TNFα in response to R-848 (Fig. 4B) . Because R-848 does not seem to activate mouse TLR8 (33), all of its effect would be expected to require TLR7. In humans, however, R-848 can activate both TLR7 and TLR8 (33) and can signal through MyD88-independent pathways (31). Hence, further experiments will be required to rule out the involvement of a MyD88-independent pathway or a possible interaction between TLR7 and TLR8 activation in humans. R-848 reduces tumor growth in vivo. Results showed that R-848 could regulate FcγR expression and synergize with FcγR function, so we next asked whether R-848 could improve antibody therapy in vivo. To test this, we used a solid tumor model using CT26 cells expressing human HER2/ neu (21, 22) . Here, CT26-HER2/neu colon carcinoma cells were s.c. injected into syngeneic BALB/c J mice. After 7 days to allow tumors to develop, mice were injected i.p. with antibody alone, R-848 alone, R-848 plus antibody, or vehicle alone thrice per week. Tumors were measured on each treatment day. After 13 days, there was a significantly reduced rate of growth in the mice receiving R-848 plus antibody (Fig. 5) . Statistical tests showed synergism between 4D5 and R-848 (P = 0.03) for reducing the rate of tumor growth. Hence, R-848 plus antitumor antibody leads to synergistic reduction of tumor growth in vivo. Western blotting was done to measure FcγRIIa (top), the γ-subunit (middle), and FcγRIIb (bottom). Blots represent three independent experiments. C, flow cytometry was done to measure surface expression of FcγRI (top) and FcγRIIa (bottom) using F(ab') 2 fragments of 32.2 and IV.3 antibodies, respectively, followed by F(ab') 2 goat anti-mouse FITC. The percent increases over nontreated (UT) were plotted as bar graphs. *, statistical significance at P ≤ 0.05; columns, mean (n = 3); bars, SD. D, time course of R-848 influence on FcγR expression. PBM were incubated for 0, 1, 3, or 14 h with 1 μmol/L R-848 then protein lysates were extracted and analyzed by Western blotting for FcγRIIa (top), the γ-subunit (middle), or FcγRIIb (bottom). Blots represent three independent experiments.
Discussion
Here, we have shown a link between the TLR7/8 and the Fcγ receptor pathways, in which TLR7/8 activation regulates FcγR expression. There is also functional synergism between these two pathways, leading to enhanced FcγR-mediated cytokine release and to a decreased rate of tumor growth. As such, TLR7/8 agonists may be of special benefit in conjunction with antibody therapy against tumors.
Several possible mechanisms may account for the functional synergism between TLR7/8 activation and FcγR activity. First, as shown in Fig. 2 and Table 1 , there was increased expression of the activating FcγR and a marked reduction in the inhibitory FcγRIIb. This would promote superadditive responses, as the FcγR would respond more strongly to any given stimulus. With regard to the synergism seen in the murine solid tumor model (Fig. 5) , other factors may also contribute. T cells, B cells, dendritic cells, and monocytes/macrophages can all respond to TLR7/8 ligands (34) , although it has also been reported that T cells may respond only indirectly (35) . Natural killer cells are themselves unaffected by R-848 treatment but respond to monocyte-derived cytokines following R-848 treatment (data not shown; ref. 36) . In mice, it has been shown that R-848 elicits cytokine production (23) as well as driving leukocytes from circulation to peripheral organs (35) . Together, these two effects might work with the increased FcγR to enhance the antitumor response. First, greater cytokine production would lead to more activation of the immune cells. Second, because migration of leukocytes into peripheral organs is stimulated, presumably there would be more leukocytes migrating to the tumor site as well (35) . In addition, R-848 may have shifted the macrophages toward an M1 phenotype and this would have significantly enhanced their ability to combat the tumors. Tumor-associated macrophages possess an M2 phenotype and promote invasion (see refs. 37, 38 for review). However, it has been shown that treatment of squamous cell carcinoma with imiquimod, a TLR7 ligand approved for clinical use, leads to an M1 and Th1 phenotype (39) . Collectively, these factors may have contributed to the synergism we observed between TLR7/8 and FcγR. Studies are ongoing to determine the precise mechanisms.
The cytokine response itself is likely responsible for the increase in activating FcγR and might have been responsible for changes in FcγRIIb as well. Upregulation of FcγR by TLR4 has been previously shown in a murine model of arthritis and was found to be largely mediated by IL-10 production (40). IL-10 can lead to increases in activating FcγR (41) (42) (43) as well as that of the inhibitory FcγRIIb (43, 44) . In contrast to this general upregulation, however, we found a striking decrease in FcγRIIb after TLR7/8 activation. Previous work has shown that IL-4 works with IL-10 to promote expression of FcγRIIb (13, 44) , but our microarray analysis found an ∼40-fold increase in IL-10 with no increase in IL-4 after R-848 treatment. Concurrently, TNFα and IFNγ, both known to decrease FcγRIIb expression (44, 45) , were strongly upregulated.
Hence, it seemed likely that the specific cytokine milieu elicited by R-848 was responsible for the changes in FcγR expression. Indeed, this was likely the case for the upregulation of activating FcγR, as blocking secretion with Brefeldin A abolished the R848-mediated changes. However, Brefeldin A did not prevent the R848-mediated decrease in FcγRIIb (Fig. 3B) . Further, FcγRIIb protein was decreased within 1 hour (Fig. 2D) , whereas FcγRIIb transcript remained to 4 hours (data not shown). These results strongly suggest a differential regulation of activating versus inhibitory receptors by R-848, in which autocrine/ paracrine factors drive the upregulation of activating receptors and different mechanisms-perhaps ubiquitination and proteasomal degradation-cause the almostimmediate decrease in FcγRIIb.
There is a chance that the culture conditions (10% FBS rather than autologous sera) influenced the maturation and responses of the monocytes. For example, the quantities of many growth, survival, or apoptosis factors that monocytes would normally be exposed to within circulation would have been different with the FBS culture. However, the negative controls within the experiments suggest that R-848 itself drove at least the majority of the FcγR and cytokine responses.
Results from the ADCC (Fig. 1B) and the murine solid tumor (Fig. 5 ) experiments suggest that although imidazoquinolines have previously been shown to be effective by themselves against certain tumors, they may prove especially useful as adjuvants to antibody therapy. In fact, it is plausible that part of the antitumor effect of R-848 is mediated by autoantibodies against the tumor. Such autoantibodies have been well documented in humans (46) . We found that cotreatment with antibody and R-848 led to the greatest effects (Figs. 4 and 5 ), but it is likely that more effective antibodies may elicit an even stronger TLR7/8-FcγR synergism. Many antibodies have been engineered for better FcγR binding (47, 48) and these may prove especially powerful when combined with TLR7/ 8 agonists. In summary, we have identified a unique regulatory link between TLR7/8 and FcγR. This not only has implications for the clinical setting, but also uncovers a novel biological regulatory pathway of Fcγ receptors.
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